<DOC>
	<DOCNO>NCT00607633</DOCNO>
	<brief_summary>The CandLE study maximum daily dose 32 mg candesartan 16/12.5 mg candesartan/hydrochlorothiazide objective evaluate naturalistic condition , i.e . routine medical care condition , impact antihypertensive therapy candesartan candesartan/HCT relevant medical parameter relate leave ventricular hypertrophy ( LVH ) well efficacy tolerability candesartan candesartan/HCT subject suffer essential hypertension..</brief_summary>
	<brief_title>Candesartan Candesartan/ Hydrochlorothiazide Treatment Patients With Hypertension LVH</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Hypertrophy , Left Ventricular</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>essential hypertension leave ventricular hypertrophy candesartan treatment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>essential hypertension</keyword>
	<keyword>ARB</keyword>
	<keyword>leave ventricular hypertrophy</keyword>
	<keyword>candesartan</keyword>
</DOC>